Natural product-derived therapy for Myocardial Infarction: Kaempferol-3-O-rutinoside, isolated from Solidago virgaurea – European Goldenrod, inhibits DNA damage responses, induces telomerase expression, inhibits telomere shortening, and promotes cardiomyocyte survival after myocardial infarction via up regulation of PNUTS, 29/October/2017,  9.16 am

Molecular therapy for Glaucoma: Rivoglitazone, an antihyperglycemic drug, increases Nmnat1 expression, increases NAD+ levels, improves neuronal dysfunction, and protects against glaucoma via down regulation of its target gene, 29/October/2017, 8.01 am
October 29, 2017
Natural product-derived therapy for anxiety and depression:  Cinnamon essential oil decreases PHF8 levels, increases the expression of serotonin receptors Htr1a and Htr2a, and promotes resistance to stress-induced -anxiety and -depression via down regulation of its target gene, 30/October/2017, 8.55 am
October 30, 2017
Show all

What they say

A recent study from the Institute for Cardiovascular Regeneration, Centre of Molecular Medicine, Frankfurt, Germany shows that “MicroRNA-34a regulates cardiac ageing and function.” This study was published, in the 7 March  2013 issue of Nature,  by Prof Dimmler, Boon, and others.


What we say

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that:   Natural product-derived therapy for Myocardial Infarction: Kaempferol-3-O-rutinoside, isolated from Solidago virgaurea – European Goldenrod, inhibits DNA damage responses, induces telomerase expression, inhibits telomere shortening, and promotes cardiomyocyte survival after myocardial infarction via up regulation of PNUTS

price-300[easy_payment currency=”USD”]


From Significance of the study to Public Health relevance:

Given that: (1)  cardiovascular disease is the leading cause of death worldwide; (2) out of 55 million deaths that occur every year, nearly 18.33 million deaths are due to cardiovascular causes; (3) the raise of death rate, due to cardiovascular disease, has increased from  123 lakhs in 1990 to 173 lakhs in 2013; (4) 85% of people over 80 years are susceptible to cardiovascular diseases;(5) in India, in 2004, 14.6 lakhs deaths (14% of total deaths) were due to ischemic heart disease; (6) the death due to cardiovascular disease is higher in low-to-middle income countries compared to developed countries; (7) the global economic cost spent in the treatment of cardiovascular disease in 2011 was little more than 10 billion US dollars;  and (8) an alarming number of people, such as 230 lakhs people, will die from cardiovascular diseases each year from 2030 onwards, there is an urgent need to find: (i) a way to induce regeneration of cardiomyocytes that were lost in Myocardial patients; (ii) a cheaper alternative to the existing expensive drugs; and (iv) a side-effect-free natural product-based drug.


From Research Findings to Therapeutic Opportunity

This study provides a natural product-based therapy for myocardial infarction.

Figure 1. Kaempferol-3-O-rutinoside functions as a Cardioprotective agent. Mechanistic insights into how Kaempferol-3-O-rutinoside induces the expression of PNUTS and Telomerase to prevent myocardial infarction and promote Cardiac regeneration/survival

Kaempferol-3-O-rutinoside, by increasing the expression of their target genes, it may increase the expression of PNUTS (fig.1)Thereby, it may: (1) inhibit DNA damage responses, (2) increase telomerase expression, (3) inhibit telomere shortening; (4) promote cardiomyocyte survival/regeneration; (5) decelerate ageing; and (6) extend life span (fig 1). 

Thus, by treating patients with  Kaempferol-3-O-rutinoside, one may prevent ageing-associated (or, stress-associated) decline in cardiac function. Together, this study suggests that pharmacological formulations encompassing “Kaempferol-3-O-rutinoside  or its analogs, either alone or in combination with other drugs”  may be used to improve cardiac function after myocardial infarction (fig. 3).  


Details of the research findings: 

Idea Proposed/Formulated (with experimental evidence) by:

Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Undisclosed mechanistic information: How Kaempferol-3-O-rutinoside increases the expression of PNUTS/Telomerase

Amount: $300#

# Research cooperation

For purchase and payment details, you may reach us at admin@genomediscovery.org


References:

Web:http://genomediscovery.org or http://newbioideas.com/

CitationBoominathan, L.,  Natural product-derived therapy for Myocardial Infarction: Kaempferol-3-O-rutinoside, isolated from Solidago virgaurea – European Goldenrod, inhibits DNA damage responses, induces telomerase expression, inhibits telomere shortening, and promotes cardiomyocyte survival after myocardial infarction via up regulation of PNUTS, 29/October/2017,  9.16 am,  Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite drop us a line at admin@genomediscovery.org

Comments are closed.